Azenta (NASDAQ:AZTA) Raised to Buy at Wall Street Zen

Azenta (NASDAQ:AZTA – Get Free Report) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also commented on the stock. Weiss Ratings raised shares of Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Needham & Company LLC increased their price objective on shares of Azenta from $37.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, November 11th. Finally, Jefferies Financial Group lifted their target price on shares of Azenta from $44.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $47.60.

Read Our Latest Report on AZTA

Azenta Price Performance

Shares of NASDAQ:AZTA opened at $45.65 on Friday. Azenta has a one year low of $15.93 and a one year high of $50.06. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -12.61 and a beta of 1.47. The firm has a 50 day simple moving average of $36.52 and a 200 day simple moving average of $28.56.

Azenta (NASDAQ:AZTA – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.17. The company had revenue of $167.09 million for the quarter, compared to analysts’ expectations of $160.16 million. Azenta had a positive return on equity of 1.41% and a negative net margin of 26.86%. As a group, analysts expect that Azenta will post 0.69 EPS for the current year.

Institutional Investors Weigh In On Azenta

A number of hedge funds have recently modified their holdings of AZTA. Green Alpha Advisors LLC lifted its stake in Azenta by 3.5% in the third quarter. Green Alpha Advisors LLC now owns 9,187 shares of the company’s stock worth $321,000 after purchasing an additional 313 shares during the last quarter. Global Retirement Partners LLC boosted its position in Azenta by 82.3% during the third quarter. Global Retirement Partners LLC now owns 771 shares of the company’s stock valued at $27,000 after buying an additional 348 shares during the period. Allworth Financial LP grew its stake in shares of Azenta by 27.9% during the third quarter. Allworth Financial LP now owns 2,421 shares of the company’s stock valued at $84,000 after buying an additional 528 shares during the last quarter. Illinois Municipal Retirement Fund grew its stake in shares of Azenta by 2.8% during the third quarter. Illinois Municipal Retirement Fund now owns 22,864 shares of the company’s stock valued at $798,000 after buying an additional 620 shares during the last quarter. Finally, Heritage Family Offices LLP bought a new position in shares of Azenta during the third quarter valued at about $31,000. Institutional investors own 99.08% of the company’s stock.

Key Stories Impacting Azenta

Here are a few of the latest stories about AZTA:

  • Positive Sentiment: Better-than-expected quarterly results helped fuel buying: Azenta reported earnings of $0.28 per share versus analysts’ $0.11 estimate, and revenue of $167.1 million, above the $160.2 million consensus. Shares subsequently reached a 52-week high. Article: Azenta Reaches New 52-Week High Following Better-Than-Expected Earnings
  • Positive Sentiment: Needham raised its price target to $57 from $37 and maintained a Buy rating, signaling greater optimism about potential upside. Article: Needham Raises Azenta Price Target
  • Positive Sentiment: Coverage highlighted commercial execution and new gene-synthesis capabilities as factors supporting Azenta’s outlook. KeyCorp’s estimates call for $0.69 EPS in FY2027 and $0.84 in FY2028; these are analyst forecasts, not company guidance. Article: Azenta Q3 Deep Dive

About Azenta

(Get Free Report)

Azenta, Inc. provides products and services for life sciences research and the management of biological samples. Its offerings include automated sample storage systems, laboratory automation equipment, consumables, and software used to track and manage samples. The company also provides genomic services through GENEWIZ, including sequencing and other genetic analysis services for researchers and organizations in the life sciences and pharmaceutical industries. Azenta was formed in 2021 when Brooks Automation separated its life sciences business and adopted the Azenta name.

See Also

Analyst Recommendations for Azenta (NASDAQ:AZTA)

Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.